Medicine and Health

Extended-release ketamine tablets for treatment-resistant depression: a randomized placebo-controlled phase 2 trial

P. Glue, C. Loo, et al.

This multicenter trial by Paul Glue and colleagues explored the effectiveness of extended-release ketamine tablets (R-107) for treatment-resistant major depression. Results showed significant improvement in depressive symptoms, particularly in the 180 mg group, while maintaining excellent tolerability. Experience minimal side effects like headaches and dizziness, and discover how R-107 is paving a new path in depression treatment.

00:00

~3 min • Beginner • English

Related Publications

Explore these studies to deepen your understanding of the subject.

Medicine and Health

A randomized, double-blind, active placebo-controlled study of efficacy, safety, and durability of repeated vs single subanesthetic ketamine for treatment-resistant depression

P. R. Shiroma, P. Thuras, et al.

Psychology

Home-based transcranial direct current stimulation treatment for major depressive disorder: a fully remote phase 2 randomized sham-controlled trial

R. D. Woodham, S. Selvaraj, et al.

Medicine and Health

Rapid neuroplasticity changes and response to intravenous ketamine: a randomized controlled trial in treatment-resistant depression

J. Kopelman, T. A. Keller, et al.

Psychology

Psilocybin for treatment-resistant depression without psychedelic effects: study protocol for a 4-week, double-blind, proof-of-concept randomised controlled trial

M. I. Husain, D. M. Blumberger, et al.

Listen, Learn & Level Up

Over 10,000 hours of research content in 25+ fields, available in 12+ languages.

No more digging through PDFs, just hit play and absorb the world's latest research in your language, on your time.

listen to research audio papers with researchbunny